Europe Rett Syndrome Market - Industry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF EUROPE RETT SYNDROME MARKET 23
1.4 CURRENCY AND PRICING 25
1.5 LIMITATIONS 25
1.6 MARKETS COVERED 25
2 EUROPE RETT SYNDROME MARKET: SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 DBMR TRIPOD DATA VALIDATION MODEL 30
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33
2.6 MULTIVARIATE MODELLING 34
2.7 DBMR MARKET POSITION GRID 35
2.8 SECONDARY SOURCES 37
2.9 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
5 REGULATORY FRAMEWORK 43
5.1 EUROPE RETT SYNDROME MARKET: REGULATIONS 43
6 MARKET OVERVIEW 44
6.1 DRIVERS 46
6.1.1 INCREASED PREVALENCE OF RETT SYNDROME 46
6.1.2 EUROPE RISE IN FEMALE POPULATION 46
6.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR RETT SYNDROME 47
6.1.4 REIMBURSEMENT FOR RETT SYNDROME 47
6.1.5 INCREASING PIPELINE CANDIDATE IN THE MARKET 48
6.2 RESTRAINTS 48
6.2.1 HIGH MEDICAL COST 48
6.2.2 HIGH COMPLEXITY IN RETT SYNDROME 48
6.2.3 SIDE-EFFECTS ASSOCIATED WITH THE USE OF MEDICATED DRUGS WHILE UNDERGOING TREATMENT FOR RETT SYNDROME 49
6.2.4 STRICT REGULATORY FRAMEWORK 49
6.3 OPPORTUNITIES 49
6.3.1 INCREASED FOCUS ON GENE THERAPY 49
6.3.2 GOVERNMENT INITIATIVES FOR RETT SYNDROME 50
6.3.3 INCREASING HEALTHCARE EXPENDITURE 50
6.4 CHALLENGES 50
6.4.1 LOW AWARENESS IN SOCIETY 50
6.4.2 LACK OF HOSPITALS RESEARCH INSTITUTE FOCUSING ON RETT SYNDROME 51
7 IMPACT OF COVID-19 ON EUROPE RETT SYNDROME MARKET 52
7.1 IMPACT ON PRICE 52
7.2 IMPACT ON DEMAND 52
7.3 IMPACT ON SUPPLY CHAIN 53
7.4 STRATEGIC DECISION 53
7.5 CONCLUSION 53
8 EUROPE RETT SYNDROME MARKET, BY TYPES 55
8.1 OVERVIEW 56
8.2 CLASSIC RETT SYNDROME 57
8.3 ATYPICAL RETT SYNDROME 57
9 EUROPE RETT SYNDROME MARKET, BY STAGES 58
9.1 OVERVIEW 59
9.2 STAGE I:EARLY ONSET 60
9.3 STAGE II RAPID DESTRUCTION 60
9.4 STAGE III PLATEAU 61
9.5 STAGE IV:LATE MOTOR DETERIORATION 61
10 EUROPE RETT SYNDROME MARKET, BY TREATMENT TYPE 62
10.1 OVERVIEW 63
10.2 DRUG CLASS 64
10.2.1 ANTIEPILEPTIC DRUGS 65
10.2.1.1 CARBAMAZEPINE 65
10.2.1.2 TOPIRAMATE 65
10.2.1.3 LAMOTRIGINE 65
10.2.1.4 OTHERS 65
10.2.2 ANTIPSYCHOTICS 65
10.2.2.1 ARIPIPRAZOLE 66
10.2.2.2 RISPERIDONE 66
10.2.2.3 OTHERS 66
10.2.3 ANTI-REFLUX AGENTS 66
10.2.3.1 OMEPRAZOLE 66
10.2.3.2 LANSOPRAZOLE 66
10.2.3.3 RABEPRAZOLE 67
10.2.3.4 OTHERS 67
10.2.4 COGNITIVE ENHANCER 67
10.2.4.1 GALANTAMINE 67
10.2.4.2 DONEPEZIL 67
10.2.4.3 OTHERS 67
10.2.5 INSOMNIA DRUGS 67
10.2.5.1 MELATONIN 68
10.2.5.2 ZOLPIDEM 68
10.2.5.3 OTHERS 68
10.2.6 OTHERS 68
10.3 THERAPY TYPE 68
10.3.1 PHYSICAL THERAPY 69
10.3.2 SPEECH THERAPY 69
10.3.3 OCCUPATIONAL THERAPY 69
10.3.4 BEHAVIORAL THERAPY 69
10.3.5 OTHERS 69
10.4 OTHERS 70
11 EUROPE RETT SYNDROME MARKET, BY DRUG TYPE 71
11.1 OVERVIEW 72
11.2 GENERICS 73
11.3 BRANDED 74
11.3.1 LAMICTAL 74
11.3.2 RISPERDAL 74
11.3.3 ABILIFY 74
11.3.4 TEGRETOL 75
11.3.5 ONFI 75
11.3.6 SLENYTO 75
11.3.7 OTHERS 75
12 EUROPE RETT SYNDROME MARKET, BY ROUTE OF ADMINISTRATION 76
12.1 OVERVIEW 77
12.2 ORAL 78
12.3 PARENTERAL 78
12.3.1 INTRAVENOUS 79
12.3.2 INTRAMUSCULAR 79
12.3.3 SUBCUTANEOUS 79
12.4 OTHERS 80
13 EUROPE RETT SYNDROME MARKET, BY END USER 81
13.1 OVERVIEW 82
13.2 HOSPITALS 83
13.3 RESEARCH ORGANISATION 83
13.4 SPECIALTY CLINICS 84
13.5 OTHERS 84
14 EUROPE RETT SYNDROME MARKET, BY DISTRIBUTION CHANNEL 85
14.1 OVERVIEW 86
14.2 HOSPITAL PHARMACY 87
14.3 ONLINE PHARMACY 88
14.4 RETAIL PHARMACY 88
14.5 OTHERS 89
15 EUROPE RETT SYNDROME MARKET, BY COUNTRY 90
15.1 GERMANY 96
15.2 FRANCE 101
15.3 U.K 105
15.4 ITALY 109
15.5 SPAIN 113
15.6 NETHERLANDS 117
15.7 RUSSIA 122
15.8 SWITZERLAND 126
15.9 TURKEY 131
15.10 AUSTRIA 135
15.11 NORWAY 139
15.12 HUNGARY 143
15.13 LITHUANIA 148
15.14 IRELAND 153
15.15 POLAND 157
15.16 REST OF EUROPE 161
16 EUROPE RETT SYNDROME MARKET: COMPANY LANDSCAPE 162
16.1 COMPANY SHARE ANALYSIS: EUROPE 162
17 SWOT ANALYSIS 163
18 COMPANY PROFILE 164
18.1 GLAXOSMITHKLINE PLC 164
18.1.1 COMPANY SNAPSHOT 164
18.1.2 REVENUE ANALYSIS 164
18.1.3 PRODUCT PORTFOLIO 165
18.1.4 RECENT DEVELOPMENTS 165
18.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 166
18.2.1 COMPANY SNAPSHOT 166
18.2.2 REVENUE ANALYSIS 166
18.2.3 PRODUCT PORTFOLIO 167
18.2.4 RECENT DEVELOPMENT 167
18.3 H. LUNDBECK A/S 168
18.3.1 COMPANY SNAPSHOT 168
18.3.2 REVENUE ANALYSIS 168
18.3.3 PRODUCT PORTFOLIO 169
18.3.4 RECENT DEVELOPMENTS 169
18.4 OTSUKA PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF OTSUKA HOLDINGS CO., LTD.) 170
18.4.1 COMPANY SNAPSHOT 170
18.4.2 REVENUE ANALYSIS 170
18.4.3 PRODUCT PORTFOLIO 171
18.4.4 RECENT DEVELOPMENTS 171
18.5 NOVARTIS AG 172
18.5.1 COMPANY SNAPSHOT 172
18.5.2 REVENUE ANALYSIS 172
18.5.3 PRODUCT PORTFOLIO 173
18.5.4 RECENT DEVELOPMENT 173
18.6 AMNEAL PHARMACEUTICALS LLC 174
18.6.1 COMPANY SNAPSHOT 174
18.6.2 REVENUE ANALYSIS 174
18.6.3 PRODUCT PORTFOLIO 175
18.6.4 RECENT DEVELOPMENTS 175
18.7 AMO PHARMA 176
18.7.1 COMPANY SNAPSHOT 176
18.7.2 PIPELINE PRODUCT PORTFOLIO 176
18.7.3 RECENT DEVELOPMENT 176
18.8 ASPEN HOLDINGS 177
18.8.1 COMPANY SNAPSHOT 177
18.8.2 REVENUE ANALYSIS 177
18.8.3 PRODUCT PORTFOLIO 178
18.8.4 RECENT DEVELOPMENT 178
18.9 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA) 179
18.9.1 COMPANY SNAPSHOT 179
18.9.2 REVENUE ANALYSIS 179
18.9.3 PRODUCT PORTFOLIO 180
18.9.4 RECENT DEVELOPMENTS 180
18.10 CIPLA INC. 181
18.10.1 COMPANY SNAPSHOT 181
18.10.2 REVENUE ANALYSIS 181
18.10.3 PRODUCT PORTFOLIO 182
18.10.4 RECENT DEVELOPMENT 182
18.11 DR. REDDYS LABORATORIES LTD. 183
18.11.1 COMPANY SNAPSHOT 183
18.11.2 REVENUE ANALYSIS 183
18.11.3 PRODUCT PORTFOLIO 184
18.11.4 RECENT DEVELOPMENTS 184
18.12 GLENMARK PHARMACEUTICAL INC., USA (A SUBSIDIARY OF GLENMARK PHAMACEUTICALS LTD.) 185
18.12.1 COMPANY SNAPSHOT 185
18.12.2 REVENUE ANALYSIS 185
18.12.3 PRODUCT PORTFOLIO 186
18.12.4 RECENT DEVELOPMENTS 186
18.13 HIKMA PHARMACEUTICALS PLC 187
18.13.1 COMPANY SNAPSHOT 187
18.13.2 REVENUE ANALYSIS 188
18.13.3 PRODUCT PORTFOLIO 188
18.13.4 RECENT DEVELOPMENTS 189
18.14 LUPIN 190
18.14.1 COMPANY SNAPSHOT 190
18.14.2 REVENUE ANALYSIS 190
18.14.3 PRODUCT PORTFOLIO 191
18.14.4 RECENT DEVELOPMENTS 191
18.15 PFIZER INC. 192
18.15.1 COMPANY SNAPSHOT 192
18.15.2 REVENUE ANALYSIS 192
18.15.3 PRODUCT PORTFOLIO 193
18.15.4 RECENT DEVELOPMENTS 193
18.16 SUN PHARMACEUTICAL INDUSTRIES LTD. 194
18.16.1 COMPANY SNAPSHOT 194
18.16.2 REVENUE ANALYSIS 194
18.16.3 PRODUCT PORTFOLIO 195
18.16.4 RECENT DEVELOPMENTS 195
18.17 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 196
18.17.1 COMPANY SNAPSHOT 196
18.17.2 REVENUE ANALYSIS 196
18.17.3 PRODUCT PORTFOLIO 197
18.17.4 RECENT DEVELOPMENTS 197
18.18 UCB S.A. 198
18.18.1 COMPANY SNAPSHOT 198
18.18.2 REVENUE ANALYSIS 198
18.18.3 PRODUCT PORTFOLIO 199
18.18.4 RECENT DEVELOPMENT 199
18.19 VIATRIS INC. 200
18.19.1 COMPANY SNAPSHOT 200
18.19.2 REVENUE ANALYSIS 200
18.19.3 PRODUCT PORTFOLIO 201
18.19.4 RECENT DEVELOPMENTS 201
18.20 ZYDUS CADILA 202
18.20.1 COMPANY SNAPSHOT 202
18.20.2 REVENUE ANALYSIS 202
18.20.3 PRODUCT PORTFOLIO 203
18.20.4 RECENT DEVELOPMENT 203
19 QUESTIONNAIRE 204
20 RELATED REPORTS 208